trial · primary record
Rapcabtagene autoleucel single agent
Chronic Lymphocytic Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 218 |
| Primary completion | 2027-07-24 |
| Primary endpoint | Phase 1: Dose recommendation: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only) |
| Registry ID | NCT03960840 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:05.067Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03960840
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.